Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Q3 2025 value amounting to -$3.6 million.

  • Lineage Cell Therapeutics' Free Cash Flow rose 3849.81% to -$3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.9 million, marking a year-over-year increase of 945.96%. This contributed to the annual value of -$23.7 million for FY2024, which is 1909.37% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Free Cash Flow stood at -$3.6 million for Q3 2025, which was up 3849.81% from -$5.6 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' Free Cash Flow's 5-year high stood at $21.9 million during Q1 2022, with a 5-year trough of -$11.4 million in Q1 2023.
  • Over the past 5 years, Lineage Cell Therapeutics' median Free Cash Flow value was -$5.8 million (recorded in 2024), while the average stood at -$4.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first surged by 39398.79% in 2022, then tumbled by 15229.21% in 2023.
  • Quarter analysis of 5 years shows Lineage Cell Therapeutics' Free Cash Flow stood at -$6.0 million in 2021, then plummeted by 37.68% to -$8.3 million in 2022, then grew by 26.27% to -$6.1 million in 2023, then decreased by 9.84% to -$6.7 million in 2024, then soared by 45.94% to -$3.6 million in 2025.
  • Its Free Cash Flow was -$3.6 million in Q3 2025, compared to -$5.6 million in Q2 2025 and -$5.0 million in Q1 2025.